Fermenta Biotech Ltd

- Planned capex of approximately ₹150 to ₹200 Crores over the next 2-3 years. - Initial ₹50-60 Crores expected to be spent in the current year. - Investments focused on: - Expansion of Vitamin D3 capacity (additional 22-25% planned). - Setting up new facilities for nutritional ingredients like minerals and Vitamin K1. - Establishment of a premix plant for combining various minerals and vitamins. - Enhancements in fermentation capacities through a new greenfield project in Saykha. - Utilization and expansion in existing plants where feasible. - Current Vitamin D3 capacity expansion partly commercialized; full commissioning expected by Q2 FY2022. - Strategic focus on strengthening nutritional ingredient portfolio and value-added vitamin D3 formats.

- The company aims to grow both topline and margins, targeting a four-digit crore revenue in 4-6 years depending on efficiency of plan implementation (Page 15). - Expect human vitamin D3 volumes to continue growing, though growth rate may taper post-COVID; animal segment worst phase is likely over, expected to stabilize (Page 12-13). - Capacity expansions, including 25% additional vitamin D3 capacity (plant IV), expected to be fully commissioned by Q2 FY2022, boosting volumes (Page 13-14). - New nutritional ingredient products like vitamin K1, premixes, minerals to contribute 30-40% revenue over next 4-5 years, supporting growth and diversification (Page 14). - CAGR for medium-term revenue growth not precisely stated but implied steady sustainable growth with margin target of ~25% EBITDA (Page 14-15). - Continued focus on new client acquisition and expanding market share in human vitamin D3, especially in the US (Page 9).

- Fermenta Biotech aims to achieve a four-digit crore topline in 4-6 years, focusing on both revenue and margin growth, with an emphasis on improving margins (Page 14). - The company expects new products and forward/backward integration to grow nutritional ingredients to contribute 30-40% of increased revenues in 4-5 years (Page 14). - Target EBITDA margin is approximately 25%, despite potential volatility from new products entering the market (Page 14). - Capex plans of Rs. 150-200 Crores over the next 2-3 years will drive capacity expansions in vitamin D3, minerals, vitamin K1, and premix plants enhancing growth potential (Page 8, 13). - Human nutrition capacity is near full utilization (~100%), with expansions expected to commission by Q2 FY2022, which should support volume and earnings growth (Page 12, 8). - Animal nutrition segment is gradually recovering from a depressed market and further price improvements are anticipated (Page 11, 12). - Business losses and one-time provisions from subsidiaries are expected to reduce, improving consolidated profitability going forward (Page 15, 17).

- The transcript does not explicitly mention the current or expected order book or pending orders for Fermenta Biotech Limited. - Discussion focuses more on capacity expansion, product launches (such as 25-hydroxy-VD3), and market outlook. - The company highlights delays due to resource allocation but confirms ongoing efforts to commercialize new products. - Capacity utilization is near full on the human nutrition side, indicating healthy demand. - Expansion projects for vitamin D3 capacity are underway with commissioning expected mostly by Q2 FY2022. - No specific figures or timelines related to order book or pending orders are provided in the transcript.

- No specific mention of any current or future fundraising through debt or equity was made in the transcript. - The company has undertaken significant capex (around Rs.150-200 Crores planned over 2-3 years) funded so far by internal accruals. - There is mention of managing existing debt, with rental income servicing about Rs.75 Crores of loans comfortably. - No indications of raising fresh equity or debt capital were discussed during the call. - Focus appears to be on utilizing internal resources and operational cash flows for expansion and project funding. - The company is monitoring market conditions and may consider options like monetizing real estate to manage finances, but no formal plans cited.